ID   SNU-484
AC   CVCL_0100
SY   SNU484
DR   BTO; BTO:0003479
DR   EFO; EFO_0006755
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03473176
DR   cancercelllines; CVCL_0100
DR   CGH-DB; 125-1
DR   CGH-DB; 9013-4
DR   Cosmic; 685590
DR   Cosmic; 848140
DR   Cosmic; 921598
DR   Cosmic; 1067206
DR   Cosmic; 1090454
DR   Cosmic; 1294958
DR   Cosmic; 1528875
DR   Cosmic; 2484965
DR   Cosmic; 2646591
DR   Cosmic; 2807646
DR   EGA; EGAS00001000610
DR   GEO; GSM1374892
DR   IARC_TP53; 7419
DR   KCLB; 00484
DR   PharmacoDB; SNU484_1467_2019
DR   Wikidata; Q54955211
RX   PubMed=9033653;
RX   PubMed=10812166;
RX   PubMed=15723654;
RX   PubMed=18804159;
RX   PubMed=19956504;
RX   PubMed=24807215;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=29435981;
RX   PubMed=32028591;
CC   Part of: Seoul National University (SNU) cell line collection.
CC   Population: Korean.
CC   Doubling time: 34 hours (PubMed=29435981).
CC   HLA typing: A*24:02,24:02; B*44:05,51:01; C*05:01,14:02; DQB1*04:01,04:01 (PubMed=25960936).
CC   HLA typing: A*24:02,30:01; B*44:02,51:01; C*05:01,14:02 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Homozygous (PubMed=9033653).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Stomach; UBERON=UBERON_0000945.
ST   Source(s): KCLB; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 9
ST   D13S317: 11,12
ST   D16S539: 13
ST   D18S51: 13,15
ST   D21S11: 30
ST   D3S1358: 18
ST   D5S818: 10
ST   D7S820: 12
ST   D8S1179: 14
ST   FGA: 19,23
ST   Penta D: 12
ST   Penta E: 22
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 18
DI   NCIt; C4004; Gastric adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   53Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 31
//
RX   PubMed=9033653; DOI=10.1002/(SICI)1097-0215(19970207)70:4<443::AID-IJC12>3.0.CO;2-G;
RA   Park J.-G., Yang H.-K., Kim W.-H., Chung J.-K., Kang M.-S., Lee J.-H.,
RA   Oh J.H., Park H.-S., Yeo K.-S., Kang S.H., Song S.-Y., Kang Y.K.,
RA   Bang Y.-J., Kim Y.I., Kim J.-P.;
RT   "Establishment and characterization of human gastric carcinoma cell
RT   lines.";
RL   Int. J. Cancer 70:443-449(1997).
//
RX   PubMed=10812166; DOI=10.1016/S0165-4608(99)00217-4;
RA   Chun Y.-H., Kil J.-I., Suh Y.-S., Kim S.-H., Kim H., Park S.-H.;
RT   "Characterization of chromosomal aberrations in human gastric
RT   carcinoma cell lines using chromosome painting.";
RL   Cancer Genet. Cytogenet. 119:18-25(2000).
//
RX   PubMed=15723654; DOI=10.1111/j.1349-7006.2005.00016.x;
RA   Takada H., Imoto I., Tsuda H., Sonoda I., Ichikura T., Mochizuki H.,
RA   Okanoue T., Inazawa J.;
RT   "Screening of DNA copy-number aberrations in gastric cancer cell lines
RT   by array-based comparative genomic hybridization.";
RL   Cancer Sci. 96:100-110(2005).
//
RX   PubMed=18804159; DOI=10.1016/j.ygeno.2008.08.002;
RA   Jung J.-J., Jeung H.-C., Chung H.C., Lee J.O., Kim T.S., Kim Y.T.,
RA   Noh S.H., Rha S.Y.;
RT   "In vitro pharmacogenomic database and chemosensitivity predictive
RT   genes in gastric cancer.";
RL   Genomics 93:52-61(2009).
//
RX   PubMed=19956504; DOI=10.4143/crt.2005.37.1.1;
RA   Ku J.-L., Park J.-G.;
RT   "Biology of SNU cell lines.";
RL   Cancer Res. Treat. 37:1-19(2005).
//
RX   PubMed=24807215; DOI=10.1038/ncomms4830;
RA   Liu J.-F., McCleland M.L., Stawiski E.W., Gnad F., Mayba O., Haverty P.M.,
RA   Durinck S., Chen Y.-J., Klijn C., Jhunjhunwala S., Lawrence M.,
RA   Liu H.-B., Wan Y.-N., Chopra V.S., Yaylaoglu M.B., Yuan W.-L., Ha C.,
RA   Gilbert H.N., Reeder J., Pau G., Stinson J., Stern H.M., Manning G.,
RA   Wu T.D., Neve R.M., de Sauvage F.J., Modrusan Z., Seshagiri S.,
RA   Firestein R., Zhang Z.-M.;
RT   "Integrated exome and transcriptome sequencing reveals ZAK isoform
RT   usage in gastric cancer.";
RL   Nat. Commun. 5:3830.1-3830.8(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=29435981; DOI=10.1002/ijc.31304;
RA   Kim H.J., Kang S.K., Kwon W.S., Kim T.S., Jeong I., Jeung H.-C.,
RA   Kragh M., Horak I.D., Chung H.C., Rha S.Y.;
RT   "Forty-nine gastric cancer cell lines with integrative genomic
RT   profiling for development of c-MET inhibitor.";
RL   Int. J. Cancer 143:151-159(2018).
//
RX   PubMed=32028591; DOI=10.3390/cancers12020334;
RA   Kim J.W., Min A., Im S.-A., Jang H., Kim Y.J., Kim H.-J., Lee K.-H.,
RA   Kim T.-Y., Lee K.W., Oh D.-Y., Kim J.-H., Bang Y.-J.;
RT   "TDP1 and TOP1 modulation in olaparib-resistant cancer determines the
RT   efficacy of subsequent chemotherapy.";
RL   Cancers (Basel) 12:334.1-334.17(2020).
//